Stay updated on Pembrolizumab Combo in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe history page now shows a new revision label (v3.3.4) added and the previous label (v3.3.3) removed, reflecting a small maintenance update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedFooter/navigation updates: added Revision: v3.3.3; removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page header now shows Revision: v3.3.2, replacing v3.2.0. This is a routine version update and does not change trial data.SummaryDifference0.0%

- Check62 days agoChange DetectedThe funding/operating status notice at the top of the page was removed. The rest of the page content remains unchanged.SummaryDifference0.3%

- Check84 days agoChange DetectedA new version entry was added to the record history, indicating an update to the study record. The rest of the page content remains unchanged.SummaryDifference0.0%

- Check105 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference8%

Stay in the know with updates to Pembrolizumab Combo in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page.